Press Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 12, 2020-- U.S. Food and Drug Administration (FDA) Grants Conditional Approval for New Brand Name - Phexxi™ --
-
Mar 3, 2020-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Feb 26, 2020- Distinguished Career at the U.S. Food and Drug Administration in CDER and the Office of Women's Health; Significant Industry and Regulatory Expertise -
-
Dec 18, 2019- Assigns PDUFA Goal Date of May 25, 2020 -
-
Dec 2, 2019- AMPREVENCE Study Met Primary and Secondary Endpoints - a 50% Relative Risk Reduction in Chlamydia Infection and a 78% Relative Risk Reduction in Gonorrhea Infection Compared to Placebo -
-
Nov 26, 2019- Submission Supported by Phase 3 AMPOWER Data -
-
Nov 14, 2019- San Diego Business Journal Recognizes the City's Top 15 Female Business Leaders -
-
Nov 6, 2019Company on Track for Amphora NDA Resubmission to the U.S. FDA
-
Oct 24, 2019-- Conference Call Scheduled for 11:00 a.m. EST --
-
Aug 26, 2019-- Company on Track to Report Top-Line AMPREVENCE Results in November 2019 --
-
Aug 5, 2019Amphora NDA Resubmission Remains on Track for Q4 2019
-
Jul 30, 2019-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Jul 1, 2019
-
Jun 10, 2019- Strategic financing to advance the commercialization of Evofem's lead asset, Amphora® -
-
May 7, 2019Management to Host Conference Call at 11:00 a.m. EDT
-
Apr 30, 2019-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Apr 23, 2019Top-line Data Expected in the Fourth Quarter of 2019
-
Apr 11, 2019Financing to fund pre-launch commercialization activities of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal, on-demand, female contraceptive